


Please type a plus sign (+) inside this box → +

12-01-05  
1646  
PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/509,773
		Filing Date	April 14, 2005
		First Named Inventor	DELANEY, ALLEN D.
		Group Art Unit	1646
		Examiner Name	
Total Number of Pages in This Submission		Attorney Docket Number	SMAR-044

### ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <ol style="list-style-type: none"><li>1. Request for correct Filing Receipt</li><li>2. Marked-up copy of 1<sup>st</sup> page of incorrect Filing Receipt</li><li>3. Marked-up copy of 1<sup>st</sup> page of Publication</li><li>4. Marked up copy of 2<sup>nd</sup> page of Supplemental Application Data Sheet</li><li>5. Postcard</li></ol>
Remarks		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Signing Attorney/Agent (Reg. No.)	PAMELA J. SHERWOOD, 36,677 BOZICEVIC, FIELD & FRANCIS, LLP
Signature	
Date	November 29, 2005

### EXPRESS MAIL LABEL NO. EV 687 634 005 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Atty Dkt. No. SMAR-044  
USSN: 10/509,773

EXPRESS MAIL LABEL / 5097634 005 US

**REQUEST FOR  
CORRECTED FILING  
RECEIPT**

Address to:  
Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Attorney Docket	SMAR-044
Applicant	DELANEY, ALLEN D.
Serial Number	10/509,773
Filing Date	April 14, 2005
Group Art Unit	1646
Examiner Name	
Title:	<i>"CANCER ASSOCIATED PROTEIN PHOSPHATASES AND THEIR USES"</i>

Sir:

A filing receipt for the above-identified patent application has been issued by the U.S. Patent and Trademark Office (copy attached) and has been found to contain the following error(s):

- (1) Please correct the "Domestic Priority Data" as indicated on the attached marked-up copies of the incorrect Filing Receipt, Supplemental Application Data Sheet, and publication.

If for any reason a fee is found to be necessary, the Commissioner is authorized to charge such fee to Deposit Account No. 50-0815.


Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: November 29, 2005

By: Pamela J. Sherwood

Pamela J. Sherwood  
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/509,773	04/14/2005	1646	740	SMAR-044		9	8

CONFIRMATION NO. 3141

24353  
BOZICEVIC, FIELD & FRANCIS LLP  
1900 UNIVERSITY AVENUE  
SUITE 200  
EAST PALO ALTO, CA 94303

FILING RECEIPT



\*OC000000016990263\*

COPY

Date Mailed: 09/15/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Allen D. Delaney, Vancouver, CANADA;

Power of Attorney: The patent practitioners associated with Customer Number 24353.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/CA03/00393 03/19/2003

Foreign Applications

UNITED STATES OF AMERICA 6068859 03/28/2002

PLEASE MOVE UNDER  
PROPER HEADING

Projected Publication Date: 12/22/2005

REV 2-8-2005

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

Cancer associated protein phosphatases and their uses

Bozicevic, Field, & Francis

10/09/2005  
DOCKETED

Correct OPR due 10/03/05  
Priority data

## CONTINUITY INFORMATION

This application is a:  
> International Application One:  
Filing Date::

371 National Stage Filing of  
PCT/CA03/00393  
March 19, 2003

Which application::  
> Application Two:  
Filing Date::

Claims benefit from  
60/368,859  
March 28, 2002

## PRIOR FOREIGN APPLICATIONS

Foreign Application One:  
Filing Date:  
Country:  
Priority Claimed::

↑  
PLEASE REFLECT  
ON FILING  
RECEIPT

# COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number  
**WO 03/083102 A2**

(51) International Patent Classification<sup>7</sup>: C12N 9/16,  
C12Q 1/42, G01N 33/574, C12Q 1/68, G01N 33/573,  
A61K 49/00

(21) International Application Number: PCT/CA03/00393

(22) International Filing Date: 19 March 2003 (19.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/368,859 28 March 2002 (28.03.2002) US

(71) Applicant (for all designated States except US):  
KINETEK PHARMACEUTICALS, INC. [CA/CA];  
1779 West 75th Avenue, Vancouver, British Columbia  
V6P 6P2 (CA).

(72) Inventor; and

(75) Inventor/Applicant (for US only): DELANEY, Allen, D.  
[CA/CA]; 1633 West 65th Avenue, Vancouver, British Columbia V6P 2R2 (CA).

(74) Agent: SMART & BIGGAR; Kingwell, Brian, G., Box  
11560, Vancouver Centre, Suite 2200, 650 West Georgia  
Street, Vancouver, British Columbia V6B 4N8 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

COPY

WO 03/083102 A2

(54) Title: CANCER ASSOCIATED PROTEIN PHOSPHATASES AND THEIR USES

(57) Abstract: Detection of expression of the provided phosphatases in cancers is useful as a diagnostic, for determining the effectiveness of drugs, and for determining patient prognosis. The encoded polypeptides further provide a target for screening pharmaceutical agents effective in inhibiting the growth or metastasis of tumor cells. The present invention further provides methods and compositions relating to agents that specifically bind to MKPX, PTP4A1, PTPN7, FEM-2, DKFZP566K0524 or FLJ20313 for treatment and visualization of tumors in patients.